Physician profile
Ha K DO
NPI 1831325679
$827.56
in general payments reported to CMS, 2019-2025
9 companies · $215 in 2025
The $215 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $266 · 2024: $346 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $827.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $134.14 | 2023 | Xifaxan, Trulance |
| Arcutis Biotherapeutics, INC. | $132.33 | 2023 | |
| Lilly USA, LLC | $121.84 | 2025 | Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $112.76 | 2024 | Sotyktu |
| Biogen, INC. | $105.43 | 2024 | Skyclarys, Spinraza |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $104.41 | 2024 | Siliq |
| Pfizer INC. | $61.60 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.17 | 2025 | |
| Abbvie INC. | $23.88 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ha DO listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.